

From: John Lloyd <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 10/17/2016 11:14:52 AM
Subject: Emerging Trends in Antimicrobial Therapy | 7 Key Steps for Future Industry Leverage

Building on 18 Years of Expertise in AMR, SMI Presents...

Superbugs & Superdrugs USA 2016

Conference: Nov 14th & 15th | Interactive Workshops: Nov 16th
Proudly Sponsored by: Noigel LLC and Polyphor

[Register](#) | [Brochure](#) | [Speaker Interviews](#) | [Attendee List](#)

JUST 4 WEEK'S REMAIN

Dear Mr Tony Kester,

Hear from leading experts who are paving the way on tackling antibiotic resistance (AMR) when [Superbugs & Superdrugs USA](#) arrives to Iselin, New Jersey in just **4 week's time**. The truly global event has attracted an international audience from the **USA, United Kingdom, Russia, Spain, Sweden and Switzerland**.

Visit the [website](#) to download a brochure or scroll down for agenda highlights.

"...sessions focused on novel platforms and agents in the treatment and prevention of diseases caused by so-called 'Superbugs' are all of interest as they cover a broad spectrum of alternate approaches and it's always good to be cognizant of new science and potential opportunities." - Janssen

7 KEY STEPS FOR INDUSTRY LEVERAGE:

1. **Develop strategies** to enable drug discovery with John Rex (AstraZeneca), through identifying new pathways and tools in combating antimicrobial resistance.
2. Benefit from an agenda tailored towards **strengthening your antibiotic pipeline** with 12+ hours of content on ground breaking innovations.
3. Identify **new windows of opportunity** to facilitate your research from bench to bedside with a detailed spotlight on the latest government incentives and funding opportunities.
4. Stay at the forefront of **cutting edge progress** by discovering novel approaches, compounds and the development of clinical assets from European case studies.
5. Create a **competitive edge** by evaluating the zoonotic links between animals and humans to target emerging infectious diseases in a "First to Know – Fast to Market" keynote.
6. Restore antibiotic drug sensitivity to **evolve your product** by targeting mechanisms using protein resistance neutralizers.
7. **Facilitate** a recent UN declaration reaffirming the World Health Organisation's "Global Action Plan on Antimicrobial Resistance" with exclusive presentations from PAHO/WHO, NIH and BARDA.

"I'm particularly looking forward to the session on public/private partnerships ...new paradigms such as these may offer tremendous promise for the future of antibacterial development" - Pfizer

HOW TO REGISTER:

Secure your place at www.superbugs-usa.com

For last minute sponsorship and exhibitor packages, contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For delegate enquiries contact Matthew Apps on +44 (0)20 7827 6093 or email mapps@smi-online.co.uk

" I am particularly excited to hear the sessions that will be led by John Rex (Enabling drug discovery and development to address the crisis of AMR), Annaliesa Anderson (Progress towards developing vaccines) and David Cook (Targeting mechanisms of resistance using protein resistance neutralizers) - BARDA

AGENDA HIGHLIGHTS - [Download a brochure](#) for presentation details

Day One - Nov 14th 2016	Day Two - Nov 15th 2016
8.30 Registration & Coffee	8.30 Registration & Coffee
9.00 Chairman's Opening Remarks William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center	9.00 Chairman's Opening Remarks William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center
9.10 Global action plan on antimicrobial resistance Pilar Ramon-Pardo , Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO	9.10 First to know and fast to market Mahesh Kumar , Vice President, Global Biological Research and Development, Zoetis
9.50 NIAID and National Strategy for CARB Rosemarie Aurigemma , Chief, Biodefense Drug Development Section, DMID, NIAID, NIH	9.50 Novel protein-based biologics for the treatment and prevention of serious bacterial infections Anthony Simon Lynch , Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC
10.30 Morning Coffee	10.30 Morning Coffee
11.00 BARDA's end-to-end support of antibacterial product development Christopher Houchens , Branch Chief, Antibacterials Program, BARDA	11.00 Progress towards developing vaccines for the prevention of Staphylococcus aureus infections Annaliesa Anderson , Vice President and CSO Bacterial Vaccines, Pfizer
11.40 Enabling drug discovery and development to address the crisis of antimicrobial resistance John Rex , Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca	11.40 The novel strategy to fight multidrug resistance by multiple drugs synergism, based on docking in drug design and TRIZ Boris Farber , CEO, Noigel, LLC
12.20 Networking Lunch	12.20 Networking Lunch
1.30 POL7080 — Polyphor's new class of macrocycle antibiotic Daniel Obrecht , Chief Scientific Officer, Polyphor	1.30 What can be done in order to be successful? Domingo Gargallo-Viola , Co-Founder and CSO, ABAC Therapeutics
2.10 Antimicrobial combination therapy: Use and disuse William Weiss , Director of Pre-Clinical Services, University of North Texas Health Science Center	2.10 Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad spectrum activity against Class A, C and D enzymes Alita Miller , Head of Bioscience, Entasis Therapeutics
2.50 Innovative approaches to treating gram-negative infections Scott Coleman , Head of Nonclinical Development, Spero Therapeutics	2.50 Afternoon Tea
3.30 Afternoon Tea	3.20 Novel beta-lactamase inhibitors to calm the carbapenemase storm Olga Lomovskaya , Vice President, Biology, The Medicines Company
4.00 Microbial metagenomics-based antibiotic discovery David Pompliano , Co-Founder and CSO, Lodo Therapeutics	4.00 Collaborative development of novel drugs to prevent infection Ian Hayter , Projects Director, Destiny Pharma Ltd
4.40 Targeting mechanisms of resistance using protein resistance neutralizers David Cook , Chief Scientific Officer, Blueberry Therapeutics Ltd.	4.40 Chairman's Closing Remarks and Close of Day Two
5.20 Chairman's Closing Remarks and Close of Day One	

Don't forget to check out the 2 **Interactive Workshops** on Nov 16th

Secure your place and view a detailed agenda at www.superbugs-usa.com

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>